Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 … – Nasdaq
EconoTimes |
Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 …
Nasdaq NEW YORK and CLEVELAND, March 15, 2018 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases … Abeona's ABO-202 nabs Rare Pediatric Disease Designation in US for Batten disease; shares up 4% premarket |
